
The market value for therapeutics to treat HER2-negative breast cancer will increase more than fourfold between 2013 and 2023, says market research company GlobalData.
The company estimates it will increase from a value of $1.45 billion in 2013 to as much as $6.12 billion by 2023, as the treatment landscape moves away from chemotherapy to hormone therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze